Login
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc.

inhibrx.com

What Do They Do?

Develops biologic therapeutic candidates for cancer patients using protein-engineering platforms.

How Do They Make Money?

Partners pay for licenses and collaborative research, with additional payments tied to development, regulatory or commercial milestones and royalties on product sales; government agencies and private nonprofits have also provided grants. License and milestone payments are tied to the license transfer or milestone, research payments to work performed, and royalties to product sales.

FY2025 revenue

Who Are Their Customers?

Partners enter license and collaboration agreements with the company; government agencies and private nonprofit organizations provide grants.

Do Revenues Turn Into Profits?

No. It lost $140.1M in FY2025.

Operating income, FY2025
−10387% of revenue
▲ +59% (Loss) vs FY2024 (−$331.4M, −165724%)
Net income, FY2025
−10773% of revenue
▼ Turned to a loss vs FY2024 ($1.7B, 843786%)
Free cash flow, FY2025
−9987% of revenue
▲ +34% (Loss) vs FY2024 (−$197M, −98503%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −10% (Loss)
vs −$35.3M in Q3 FY2025

Who Do They Compete With?

Competes with Crescendo Biologics, Molecular Partners, Precirix, Affibody Medical, Numab Therapeutics, GT Biopharma, Sanofi, Regeneron Pharmaceuticals, Adimab, Genmab, Macrogenics, Merus, Amgen, Xencor, Zymeworks, AstraZeneca, F. Hoffmann-La Roche, Pfizer, Merck &, and Novartis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support